Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans

Este estudio ha sido identificado como potencialmente de alto impacto. La métrica de alto impacto de OE, basada en la inteligencia artificial, estima la influencia que puede tener un artículo integrando señales procedentes tanto de la revista en la que se publica como del contenido científico del propio artículo. Desarrollado mediante el procesamiento del lenguaje natural más avanzado, el modelo de Alto Impacto de OE predice con mayor precisión el futuro rendimiento de las citas de un estudio que el factor de impacto de la revista por sí solo. Esto permite reconocer antes las investigaciones clínicamente significativas y ayuda a los lectores a centrarse en los artículos con más probabilidades de configurar la práctica futura.

Resumen del estudio

Sixteen healthy subjects were included in this double-blind, placebo-controlled, cross-over study examining the single-dose kinetics and pharmacokinetic-pharmacodynamic relationships of oral lysergic acid diethylamide (LSD). Participants were given 200 μg LSD or placebo over 2 experimental test sessions with a washout period of at least 7 days between sessions. LSD and 2-oxo-3-hydroxy-lysergic acid diethylamide (O-H-LSD) concentrations in plasma and urine were determined using a validated liquid-chromatography-tandem mass-spectrometry, and drug effect was measured using the visual analogue scale. The acute subjective and sympathomimetic responses to lysergic acid diethylamide lasted up to 12 hours and were closely associated with the concentrations in plasma over time. Maximal concentrations of lysergic acid diethylamide were reached 1.5 (median, range 0.5-4) hours after administration. One percent of the orally administered LSD was eliminated in urine as LSD, and 13% was eliminated as O-H-LSD within 24 hours.